宜明昂科生物医药技术（上海）股份有限公司（宜明昂科-B，股票代码：01541）于2026年9月16日公布翌日披露报表，披露最新回购交易信息。公司于当日于香港联合交易所场内回购合计92,400股H股，占公司现有已发行股份（不含库藏股）总数的约0.0221%。回购价范围介乎每股3.155港元至3.27港元，回购数量对应的成交量加权平均价为每股3.2205港元，合计支付金额约29.76万港元。
回购完成后，宜明昂科-B已发行股份（不含库藏股）为418,205,105股，库藏股数增至2,272,200股，公司整体已发行股份总数维持于420,477,305股。本次回购授权于2026年5月28日获股东大会批准，同意公司可回购股票总数为43,150,769股，截至目前公司已合计回购2,272,200股，占授权通过当日已发行股本约0.527%。根据公告，下一次有关新发行股份或再出售库存股份的暂止期将持续至2026年10月16日。
公司在公告中确认，本次回购符合香港联合交易所有限公司证券上市规则及相关法律法规的要求。公告由执行董事、联席公司秘书关梅签署。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.